表紙:ドライアイ症候群の世界市場-2023年~2030年
市場調査レポート
商品コード
1297829

ドライアイ症候群の世界市場-2023年~2030年

Global Dry Eye Syndrome Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
ドライアイ症候群の世界市場-2023年~2030年
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

ドライアイ症候群の世界市場は、2022年に59億米ドルに達し、2030年には104億米ドルに達するなど、有利な成長が予測されています。世界のドライアイ症候群市場は、予測期間2023-2030年にCAGR 7.4%を示すと予測されています。

ドライアイ症候群の治療は、症状を軽減し、涙の生産と安定性を高め、眼表面の健康を守ることに重点を置いています。一般的な治療法には、人工涙液の使用、処方薬、点鼻プラグ、生活習慣の調整、ドライアイの原因となる基礎疾患への対処などがあります。

ドライアイ症候群の市場範囲は、タイプ、製品、剤形、販売チャネル、流通チャネルで構成され、ドライアイ症候群の市場シェアを拡大しています。ドライアイ症候群の世界市場は、ドライアイ症候群の有病率の高さ、認知度の向上と教育、国を超えた戦略的提携や協力関係などの要因の結果として拡大しており、ドライアイ症候群市場の成長にも明るい見通しが生まれています。

市場力学

ドライアイ症候群の新たな治療法の登場がドライアイ症候群市場の成長を牽引すると期待される

American Academy of Ophthalmology Article, 2022によると、ドライアイ症候群治療の分野で2つの注目すべき進展があり、Seitzman博士の興味をそそっています。ひとつはNOV03と呼ばれる薬剤で、欧州とオーストラリアではNovaTearsとして知られています。この薬剤は不活性で無水の半フッ素化アルカンパーフルオロヘキシロオクタン(F6H8)です。水、防腐剤、界面活性剤を含まない液体で、眼表面を冷却する効果があります。さらに研究者たちは、他の薬物を送達するためのビークルとしての可能性を探っています。

二つ目の注目すべき開発は、Azura Ophthalmics社が開発中の軟膏剤AZR-MD-001です。この軟膏は硫化セレンを含み、角膜溶解剤として機能します。この軟膏は、慢性的なマイボーム腺疾患、特にまぶたの縁が過角化している患者における治療に有望です。この革新的な治療法は、疾患の根本的な原因をターゲットとし、マイボーム腺の全体的な健康状態を改善することを目的としています。

NOV03とAZR-MD-001はいずれも、ドライアイ症候群の理解と治療における進歩を象徴するものです。これらの開発は、ドライアイという疾患の特定の側面に対処するための潜在的な解決策を提供し、患者やヘルスケア専門家に新たな選択肢を提供するものです。その有効性を十分に評価し、ドライアイ症候群の管理における位置づけを決定するためには、さらなる調査と臨床試験が必要です。このように、上記の要因から、予測期間中に市場は拡大すると予想されます。

ドライアイ症候群の有病率の増加がドライアイ症候群市場の成長を促進する見込み

Dry Eye Directory Report 2023によると、世界全体で約10億人がドライアイ症状を伴う一般的な疾患であるマイボーム腺機能不全に罹患しています。米国では、ドライアイの有病率は人口の5%から15%と推定されています。

米国におけるドライアイの経済的影響は大きく、年間554億米ドル以上の経済損失が発生しています。2010年12月から2020年7月にかけて動向が倍増していることからもわかるように、「ドライアイ症候群」というトピックの人気は著しく高まっています。

ドライアイ治療費の高さがドライアイ症候群市場の成長を妨げると予想される

ドライアイ治療にかかる費用は、症状の緩和を求める人々にとって大きな障害となり得る。継続的な管理の必要性やさまざまな治療オプションの利用可能性など、治療費が高額になる要因はいくつかあります。

例えば、治療計画は3~4回のセッションで800~1,000米ドルかかることもあります。最初の総合的な目の評価や、マイボーム腺発現のような追加処置は、患者が何とか調達した治療計画によって追加費用がかかる場合があります。したがって、上記の要因のために、市場は予測期間中に低迷すると予想されます。

COVID-19影響分析

COVID-19の流行はドライアイ症候群(DES)市場に大きな影響を与えています。戸締まりや社会的距離を置く措置により、DES患者の診断や治療開始が遅れています。眼科診療所や病院のキャパシティが縮小しているため、眼科専門医や診断検査へのアクセスが制限され、DESの管理や監視が困難になっています。

リモートワークやオンライン教育によるスクリーン使用時間の増加は、DESの症状を悪化させています。さらに、フェイスマスクの使用は予防には必要だが、涙の蒸発を促進し、DESの症状を悪化させる可能性があります。

パンデミックが精神衛生に及ぼす全体的な影響と、ヘルスケアシステムがCOVID-19症例の管理に重点を置いていることが相まって、DESの研究開発およびマーケティング活動から資源を逸らしています。これらの要因は、パンデミック中にDES患者が直面する課題と、革新的な解決策と眼の健康に対する支援の必要性を浮き彫りにしています。従って、これらの要因により、市場は中程度の影響を受けているが、今後数年で市場は再び牽引力を取り戻し、成長を示すと予想されます。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争は、同地域のヘルスケアシステムと住民の双方に大きな影響を及ぼしています。ヘルスケア施設は破壊されたり中断されたりしており、ドライアイ症候群(DES)の診断、治療、管理のための眼科医療サービスへのアクセスが低下しています。また、紛争は住民の避難を招き、住民はストレスや不安にさらされ、生活必需品へのアクセスが制限されることで、DESの症状の発症や悪化につながる可能性があります。

さらに、水や衛生設備を含むインフラの被害は水質に影響を与え、目の健康には適切な水分補給が不可欠であるため、DESの症状を悪化させる可能性があります。ドライアイ症候群(DES)の潤滑点眼薬やその他の治療薬を含む医薬品のサプライチェーンが戦争によって寸断されると、重要な医薬品が不足したり、入手が制限されたりします。そのため、DESの症状に対処するための適切な治療が受けられなくなる可能性があります。

さらに、進行中の紛争は、それに伴うストレス、トラウマ、不確実性を伴い、影響を受けた人々に心理的影響を与えます。不安や抑うつといった心理的苦痛や精神的健康状態は、DES症状と関連しています。従って、戦争による心理的犠牲は、間接的に被災者におけるDESの有病率の増加や重症度の上昇に寄与している可能性があります。

目次

第1章 調査手法と範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響を与える要因
    • 促進要因
      • ドライアイ症候群の新しい治療法の利用可能性
      • ドライアイ症候群の有病率の増加
    • 抑制要因
      • ドライアイ治療の高額な費用
    • 機会
      • デジタルヘルスソリューションの統合
    • 影響分析

第5章 業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19の分析

第7章 ロシアとウクライナの戦争分析

第8章 タイプ別

  • 水分欠乏
  • 蒸発性

第9章 製品別

  • 抗炎症薬
    • シクロスポリン
    • コルチコステロイド
    • 他の
  • 潤滑点眼薬
  • 涙点プラグ
    • 取り外し可能
    • 溶解性
  • 経口オメガサプリメント
  • その他

第10章 剤形別

  • ジェル
  • アイソリューション
  • カプセルと錠剤
  • 目薬
  • 軟膏

第11章 販売チャネル別

  • 処方
  • OTC

第12章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第13章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東とアフリカ

第14章 競合情勢

  • 競合シナリオ
  • 製品のベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第15章 企業プロファイル

  • Novartis AG
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • AbbVie, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • AFT Pharmaceuticals
  • Johnson &Johnson Services, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • OASIS Medical.
  • Oyster Point Pharma, Inc.
  • Bausch &Lomb

第16章 付録

目次
Product Code: PH1352

Market Overview

The Global Dry Eye Syndrome Market reached US$ 5.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 10.4 billion by 2030. The global dry eye syndrome market is expected to exhibit a CAGR of 7.4% during the forecast period 2023-2030.

Dry eye syndrome treatment focuses on reducing symptoms, enhancing tear production and stability, and safeguarding the health of the eye surface. Common treatment methods include the use of artificial tears, prescription medications, punctal plugs, lifestyle adjustments, and addressing any underlying conditions contributing to dry eye.

The dry eye syndrome market scope comprises type, product, dosage form, sales channel, and distribution channel, which has increased the dry eye syndrome market share. The global market for dry eye syndrome is expanding as a result of factors including the high prevalence of dry eye syndrome, increasing awareness and education, and strategic partnerships and collaborations across countries are also creating a positive outlook for the dry eye syndrome market growth.

Market Dynamics

The Availability of New Treatments for Dry Eye Syndrome is Expected to Drive Dry Eye Syndrome Market Growth

According to the American Academy of Ophthalmology Article, 2022, two noteworthy developments in the field of dry eye syndrome treatment have piqued the interest of Dr. Seitzman. The first is a drug called NOV03, known as NovaTears in Europe and Australia. This drug is an inert and anhydrous semifluorinated alkane perfluorohexyloctane (F6H8). It is a liquid that lacks water, preservatives, and surfactants, and it has a cooling effect on the ocular surface. Moreover, researchers are exploring its potential as a vehicle for delivering other drugs.

The second development of interest is AZR-MD-001, an ointment being developed by Azura Ophthalmics. This ointment contains selenium sulfide and functions as a keratolytic agent. It shows promise for addressing chronic meibomian gland disease, particularly in patients with hyperkeratinization of the lid margin. This innovative treatment approach aims to target the underlying causes of the disease and improve the overall health of the meibomian glands.

Both NOV03 and AZR-MD-001 represent advancements in the understanding and treatment of dry eye syndrome. These developments offer potential solutions to address specific aspects of the condition and provide new options for patients and healthcare professionals. Further research and clinical trials are needed to fully evaluate their efficacy and determine their place in the management of dry eye syndrome. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Increasing Prevalence of Dry Eye Syndrome is Expected to Drive Dry Eye Syndrome Market Growth

According to Dry Eye Directory Report 2023, globally, approximately one billion individuals are affected by Meibomian Gland Dysfunction, a common condition associated with dry eye symptoms. In the United States, the prevalence of dry eye is estimated to range from 5% to 15% of the population.

The economic impact of dry eye disease in the USA is substantial, costing the economy over $55.4 billion annually. The popularity of the topic "dry eye syndrome" has seen a significant increase, as indicated by the doubling of trends between December 2010 and July 2020.

The High Cost of Dry Eye Treatments is Expected to Hamper Dry Eye Syndrome Market Growth

The cost of dry eye treatments can be a major obstacle for individuals seeking relief from their symptoms. Several factors contribute to the high cost of treatment, including the need for ongoing management and the availability of various treatment options.

For instance, a treatment plan can cost $800 - $1000 for three or four sessions. Initial comprehensive eye assessment and additional procedures like meibomian gland expression may cost extra depending on the treatment plan the patient manages to procure. Thus, owing to the above factors, the market is expected to hamper over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has had significant impacts on the dry eye syndrome (DES) market. Lockdowns and social distancing measures have led to delayed diagnosis and treatment initiation for individuals with DES. Eye care clinics and hospitals operating at reduced capacity have limited access to eye care professionals and diagnostic tests, making it difficult to manage and monitor DES.

The increased screen time due to remote work and online education has worsened DES symptoms. Additionally, the use of face masks, while necessary for prevention, can contribute to increased evaporation of tears and aggravate DES symptoms.

The pandemic's overall impact on mental health, coupled with the healthcare system's focus on managing COVID-19 cases, has diverted resources away from DES research, development, and marketing efforts. These factors collectively highlight the challenges faced by individuals with DES during the pandemic and the need for innovative solutions and support for their ocular health. Thus, owing to these factors, the market is moderately affected and it is anticipated that the market will regain traction and show growth in the coming years.

Russia-Ukraine Conflict Analysis

The Russian-Ukraine war has had significant consequences for both the healthcare system and the population in the region. Healthcare facilities have been destroyed or disrupted, leading to reduced access to eye care services for the diagnosis, treatment, and management of Dry Eye Syndrome (DES). The conflict has also resulted in population displacement, exposing individuals to increased stress, anxiety, and limited access to necessities, which can contribute to the development or worsening of DES symptoms.

Furthermore, damage to infrastructure, including water and sanitation systems, impact water quality, potentially exacerbating DES symptoms as proper hydration is essential for eye health. The war's disruption of the medication supply chain, including lubricant eye drops and other treatments for Dry Eye Syndrome (DES), result in shortages or limited availability of crucial medications. This can hinder individuals' ability to access proper treatment for managing DES symptoms.

Additionally, the ongoing conflict, with its associated stress, trauma, and uncertainty, have psychological impacts on the affected population. Psychological distress and mental health conditions, such as anxiety and depression, have been associated with DES symptoms. Therefore, the psychological toll of the war may indirectly contribute to the higher prevalence or increased severity of DES among the affected population.

Segment Analysis

The global dry eye syndrome market is segmented based on type, product, dosage form, sales channel, distribution channel, and region.

OTC from the Sales Channel Segment Accounts for 52.3% of the Market Share Owing to Preferred First-Line Treatment for Mild to Moderate Dry Eye Syndrome

For mild to moderate cases of dry eye syndrome (DES), over-the-counter (OTC) lubricating eye drops or artificial tears are commonly recommended as the first-line treatment. These products are designed to provide temporary relief by moisturizing the eyes, reducing dryness, and relieving irritation.

OTC lubricating eye drops are readily available without a prescription and can be purchased from pharmacies, drugstores, or retail stores. They are formulated to mimic the natural tears and provide additional lubrication to the ocular surface. These drops come in different formulations, including aqueous-based, gel-based, or lipid-based, offering a variety of options to suit individual preferences and needs.

Moreover, OTC lubricating eye drops offer a convenient and accessible option for managing mild to moderate dry eye symptoms. The choice of formulation depends on individual preferences, the severity of symptoms, and the specific characteristics of the dry eye condition. However, regular use of OTC artificial tears can help alleviate discomfort, improve tear quality, and enhance overall eye comfort. Thus, owing to the above factors, the market is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 38.4% of the Market Share Owing to the Increasing Health Care Expenditure and Increasing Prevalence of Dry Eye Syndrome

According to the Dry Eye Directory 2023 Report, the prevalence of dry eye syndrome in the United States is estimated to be between 16.7 million and 50.2 million individuals, which represents 5-15% of the population. The economic impact of dry eye disease in the US is significant, costing over $55.4 billion annually.

Also, TearSolutions announced encouraging findings from its initial human trial of Lacripep, a potential treatment for dry eye disease, in September 2022. The positive results from this pipeline candidate study are expected to expedite the advancement and introduction of innovative medications, ultimately driving market expansion. Thus, from the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: Novartis AG, AbbVie, Inc., Sun Pharmaceutical Industries Ltd., Santen Pharmaceutical Co., Ltd., AFT Pharmaceuticals, Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., OASIS Medical, Oyster Point Pharma, Inc. and Bausch & Lomb.

Why Purchase the Report?

  • To visualize the global dry eye syndrome market segmentation based on the type, product, dosage form, sales channel, distribution channel and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of dry eye syndrome market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global dry eye syndrome market report would provide approximately 77 tables, 78 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Product
  • 3.3. Snippet by Dosage Form
  • 3.4. Snippet by Sales Channel
  • 3.5. Snippet by Distribution Channel
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Availability of New Treatments for Dry Eye Syndrome
      • 4.1.1.2. Increasing Prevalence of Dry Eye Syndrome
    • 4.1.2. Restraints
      • 4.1.2.1. The High Cost of Dry Eye Treatments
    • 4.1.3. Opportunity
      • 4.1.3.1. Integration of Digital Health Solutions
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type
  • 8.2. Aqueous deficiency*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Evaporative

9. By Product

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.1.2. Market Attractiveness Index, By Product
  • 9.2. Anti-inflammatory Drugs*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Cyclosporine
    • 9.2.4. Corticosteroid
    • 9.2.5. Other
  • 9.3. Lubricant Eye Drops
  • 9.4. Punctal Plugs
    • 9.4.1. Removable
    • 9.4.2. Dissolvable
  • 9.5. Oral Omega Supplements
  • 9.6. Others

10. By Dosage Form

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 10.1.2. Market Attractiveness Index, By Dosage Form
  • 10.2. Gels*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Eye Solutions
  • 10.4. Capsules & Tablets
  • 10.5. Eye Drops
  • 10.6. Ointments

11. By Sales Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 11.1.2. Market Attractiveness Index, By Sales Channel
  • 11.2. Prescription*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. OTC

12. By Distribution Channel

    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.1.2. Market Attractiveness Index, By Distribution Channel
  • 12.2. Hospital Pharmacies*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Retail Pharmacies
  • 12.4. Online Pharmacies

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 13.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 13.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 13.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
    • 13.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.2.8.1. The U.S.
      • 13.2.8.2. Canada
      • 13.2.8.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 13.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 13.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 13.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
    • 13.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.3.8.1. Germany
      • 13.3.8.2. The U.K.
      • 13.3.8.3. France
      • 13.3.8.4. Italy
      • 13.3.8.5. Spain
      • 13.3.8.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 13.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 13.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 13.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
    • 13.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.4.8.1. Brazil
      • 13.4.8.2. Argentina
      • 13.4.8.3. Rest of South America
  • 13.5. Asia Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 13.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 13.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 13.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
    • 13.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.5.8.1. China
      • 13.5.8.2. India
      • 13.5.8.3. Japan
      • 13.5.8.4. Australia
      • 13.5.8.5. Rest of Asia Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 13.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 13.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 13.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
    • 13.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Product Benchmarking
  • 14.3. Company Share Analysis
  • 14.4. Key Developments and Strategies

15. Company Profiles

  • 15.1. Novartis AG*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. AbbVie, Inc.
  • 15.3. Sun Pharmaceutical Industries Ltd.
  • 15.4. Santen Pharmaceutical Co., Ltd.
  • 15.5. AFT Pharmaceuticals
  • 15.6. Johnson & Johnson Services, Inc.
  • 15.7. Otsuka Pharmaceutical Co., Ltd.
  • 15.8. OASIS Medical.
  • 15.9. Oyster Point Pharma, Inc.
  • 15.10. Bausch & Lomb

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us